Trials / Terminated
TerminatedNCT02204904
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 59 (actual)
- Sponsor
- Genetix Biotherapeutics Inc. · Industry
- Sex
- Male
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Allo-HSCT | Allogeneic Hematopoietic Stem Cell Transplantation |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2019-12-06
- Completion
- 2019-12-06
- First posted
- 2014-07-31
- Last updated
- 2020-05-21
Locations
13 sites across 7 countries: United States, Argentina, Canada, Germany, Italy, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT02204904. Inclusion in this directory is not an endorsement.